摘要
胃肠间质瘤（GIST）是来源于消化道的间质肿瘤，靶向药物伊马替尼的出现改变了GIST的整个治疗模式，由传统的外科手术单一模式向综合应用靶向治疗、外科治疗和腔镜外科治疗的个体化治疗模式转变。文章就近年来GIST在术前活组织病理检查、腔镜外科治疗、伊马替尼新辅助治疗及伊马替尼疗效评价方面的进展作一介绍。
Gastrointestinal stromal tumor （GIST） may be defined as mesenchymal tumors of the gastrointestinal tract, and the application of the tyrosine kinase inhibitor imatinib mcsylate has changed the treatment style of the tumor.The surgical treatment is the only choice for the GIST patients before imatinib era, but now the individualized treatment combined with target therapy, surgery and laparoscope surgery becomes the mainstay. The paper focus on the new development of preoperative biopsy, laparoscope surgery, imatinib neoadjuvant and imatinib therapeutic effect evaluation in recent years.
出处
《肿瘤研究与临床》
CAS
2010年第2期74-75,共2页
Cancer Research and Clinic
关键词
胃肠道间质肿瘤
外科治疗
伊马替尼
Gastrointestinal stromal tumors
Surgical treatment
Imatinib
